BI-770371
- Generic Name
- BI-770371
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT06806852
- Locations
- ๐บ๐ธ
Norton Cancer Institute, Downtown, Louisville, Kentucky, United States
๐บ๐ธThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
๐ฆ๐บGosford Hospital, Gosford, New South Wales, Australia
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
- Conditions
- Compensated Liver CirrhosisMetabolic Dysfunction Associated Steatohepatitis (MASH)
- Interventions
- Drug: Placebo for BI 770371
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT06675929
- Locations
- ๐บ๐ธ
Blessed Health Care, Miami, Florida, United States
๐บ๐ธSouthern California Research Center, Coronado, California, United States
๐บ๐ธCatalina Research Institute, LLC-Montclair-49051, Montclair, California, United States
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT05327946
- Locations
- ๐บ๐ธ
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
๐บ๐ธJohn Theurer Cancer Center, Hackensack, New Jersey, United States
๐จ๐ฆCentre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC)MelanomaNon-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT05068102
- Locations
- ๐ณ๐ฑ
VU University Medical Center, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.